1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

  • July 2014
  • -
  • Frost & Sullivan
  • -
  • 66 pages

Summary

Table of Contents

Antiretroviral Combinations Continue to Transform the Treatment Landscape

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.

Key Findings
Human Immunodeficiency Virus (HIV) Antiretrovirals
The 2006 launch of Atripla, the first single-tablet regimen (STR) for the treatment of HIV infection, marked an important advancement in antiretroviral therapy (ART), significantly enhancing efficacy and reducing pill burden. Research has continued to build on this innovation, and patients now have at their disposal a number of STRs that are highly effective and have good tolerability. Researchers are seeking to develop novel antiretroviral combinations that have a high barrier to resistance and a low cross-resistance with existing drugs, and that are easy to administer (ideally once-daily dosing).

Given the advancements in treatment, viral breakthrough is not uncommon. Keys to maintaining viral suppression are patient adherence, strategically guided treatment choices, and novel drug development.

Promising candidates in late trials include Tobira Therapeutics’ cenicriviroc with novel anti-inflammatory effects, and Gilead’s tenofovir alafenamide (TAF), which could overcome the safety concerns associated with tenofovir.

Methodology and Scope
-This research service focuses on antiretroviral therapeutics for the treatment of infection by HIV/AIDS. It does not cover vaccines.
-A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
-The information contained in this research service was derived from published sources, including the following: disease organization Web sites; public health organization Web sites; company publications including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

HIV Overview
Human immunodeficiency virus, a bloodborne infectious disease, remains a major global health and development threat. Incidence and prevalence remain highest in Sub-Saharan Africa, with the region accounting for about % of the estimated million people living with HIV globally.

HIV infection weakens the immune system by destroying CD4 cells, and can eventually lead to acquired immune deficiency syndrome (AIDS). This is the most advanced stage of HIV infection and can take up to years to develop. Although carriers of the virus may not exhibit any symptoms, they can still transmit it.

HIV is transmitted by direct exposure to contaminated blood and other bodily fluids. Potential exposure routes include needle-stick injuries, needle sharing, blood transfusions, dialysis, tattoos and piercings, mother-to-fetus transmission, and sexual contact. High-risk populations include those with potential occupational exposure, including healthcare workers, dentists, and first responders; those practicing risky behaviors (e.g., intravenous drug users); and recipients of invasive therapeutic procedures such as blood transfusions and organ transplants (before 1985 in the United States).

ART is highly effective at suppressing the virus and boosting infected individuals’ immune systems, and at reducing the likelihood of transmission. Some million infected people are on ART; the global target is million by 2015. ART has recently been shown to be safe and effective for pre-exposure prophylaxis (PrEP) for HIV-negative people. It is not a cure, however, and must be taken for life due to the latent virus in reservoirs inaccessible to antiretrovirals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
HIV Diagnosis Market by Test Type, Viral Load, CD4 Count, Early Infant, Viral Identification, Product, End User - Global Forecast to 2021

HIV Diagnosis Market by Test Type, Viral Load, CD4 Count, Early Infant, Viral Identification, Product, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The HIV diagnosis market is projected to reach USD 3.88 billion by 2021 from USD 2.35 billion in 2016, at a CAGR of 10.5% from 2016 to 2021. The global HIV diagnosis market is segmented based on product, ...

2017 World Blood Typing, Grouping and Infectious Disease NAT Screening Market: Sales and Market Shares of Major Suppliers by Test and Country

2017 World Blood Typing, Grouping and Infectious Disease NAT Screening Market: Sales and Market Shares of Major Suppliers by Test and Country

  • $ 5450
  • Industry report
  • March 2017
  • by Venture Planning Group

This unique report from VPGMarketResearch provides sales and market share estimates for major suppliers of blood typing, grouping and infectious disease screening products by test and country. The report ...

2017 Roche: Diagnostics Sales, Market Shares and Competitive Position by Product and Country

2017 Roche: Diagnostics Sales, Market Shares and Competitive Position by Product and Country

  • $ 5000
  • Industry report
  • March 2017
  • by Venture Planning Group

This unique market intelligence report from VPGMarketResearch provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product ...


Download Unlimited Documents from Trusted Public Sources

Pathology Statistics in the US - Forecast

  • April 2017
    8 pages
  • Pathology  

  • United States  

    United Kingdom  

View report >

Mortality Industry in Asia

  • April 2017
    106 pages
  • Mortality  

    HIV AIDS  

    Depression  

  • Asia  

    India  

    World  

View report >

Global Malaria Statistics

  • April 2017
    3 pages
  • Infectious Dise...  

    Malaria  

  • World  

    Spain  

View report >

Related Market Segments :

HIV AIDS
HIV Antiviral

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.